Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ

Human Pathology

Volumn 39, Issue 4, 2008, Pages 573-578

  Kruse, Arnold Jan ^a,c   Skaland, Ivar ^a   Munk, Ane Cecilie ^a,b   Janssen, Emiel ^a   Gudlaugsson, Einar ^a   Baak, Jan P A ^a,c,d  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

AIS; CIN3s; Coexistence; p53; Retinoblastoma protein

Indexed keywords

CYCLIN D; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GRADING; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GOOD LABORATORY PRACTICE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PUNCH BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 40649105478     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.08.014     Document Type: Article

References (26)

1. Ferlay J., Bray F., Pisani P., et al. Globocan 2000. Cancer incidence, mortality and prevalence worldwide (2001), IARC Press, Lyon
2. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
3. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs (2003), IARC Press, Lyon 259-287
4. Smith H.O., Tiffany M.F., Qualls C.R., and Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 78 (2000) 97-105
5. Sasieni P., and Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 357 (2001) 1490-1493
6. Zielinsky G.D., Snijder P.J.F., Rozendaal L., et al. The presence of high-risk HPV combined with specific p53 and p16ink4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 201 (2003) 535-543
7. Poynor E.A., Barakat R.R., and Hoskins W.J. Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix. Gynecol Oncol 57 (1995) 158-164
8. Bekkers R.L., Bulten J., Wiersma-van Tilburg A., et al. Coexisting high-grade glandular and squamous cervical lesions and human papillomavirus infections. Br J Cancer 89 (2003) 886-890
9. Scheffner M., Werness B.A., and Huibregtse J.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
10. Dyson N., Howley P.M., Munger K., and Harlow E. The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 23 (1989) 934-939
11. Crook T., Tidy J.A., and Vousden K.H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67 (1991) 547-556
12. Heck D.V., Yee C.L., Howley P.M., and Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 89 (1992) 4442-4446
13. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., and Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor protein. EMBO J 8 (1989) 4099-4105
14. Baak J.P., Kruse A.J., Garland S.M., et al. Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. Am J Surg Pathol 29 (2005) 1062-1066
15. Baak J.P., Kruse A.J., Robboy S.J., Janssen E.A., Van Diermen B., and Skaland I. Dynamic behavioral interpretation of cervical intraepithelial neoplasia (CIN) by molecular biomarkers: a proposal. J Clin Pathol 59 (2006) 1017-1028
16. Mitchell H., Medley G., Gordon I., and Giles G. Cervical cytology reported as negative risk of adenocarcinomas of uterine cervix: no strong evidence of benefit. Br J Cancer 71 (1995) 894-897
17. Schwartz S.M., and Weiss N.S. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol 124 (1986) 1045-1047
18. Wright T.C., Kurman R.J., and Ferenczy A. Precancerous lesions of the cervix. In: Kurman R. (Ed). Blaustein's pathology of the female genital tract (2002), Springer-Verlag, New York, USA 293-314
19. Lickrish G.M., Colgan T.J., and Wright V.C. Colposcopy of adenocarcinoma in situ and invasive adenocarcinoma of the cervix. Obstet Gynecol Clin North Am 20 (1993) 111-122
20. Bertrand M., Lickrish G.M., and Colgan T.J. The anatomic distribution of cervical adenocarcinoma in situ: implication for the treatment. Am J Obstet Gynecol 157 (1987) 21-25
21. Christopherson W.M.M., Nealon N., and Gray L.A. Noninvasive precursor lesions of adenocarcinoma and mixed adenosquamous carcinoma of the cervix uteri. Cancer 44 (1979) 975-983
22. Ostor A.G. Early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 19 (2000) 29-38
23. Dybkaer R., Jordal R., Jorgensen P.J., et al. A quality manual for the clinical laboratory-including the elements of a quality system. Proposed guidelines. Scan J Clin Lab Invest S52 (1992) 1-27 (Draft 92-08-26)
24. Hall P.A., and Going J.J. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 35 (1999) 489-494
25. Makkink-Nombrado SV. Quantitative pathological, cell- and molecular biological markers in breast cancer. Towards more accurate prognostication and good laboratory practice in quantitative pathology. Thesis, Vrije Universiteit Amsterdam, The Netherlands, 1995, 4-9.
26. Baak J.P. The framework of pathology: good laboratory practice by quantitative and molecular methods. J Pathol 198 (2002) 277-283